News & Updates | Duchenne Muscular Dystrophy

News & Resources

Health Canada: National Strategy for Drugs for Rare Diseases Update

July 27, 2021

In January 2021, Health Canada launched a national online initiative to engage Canadians in the development of a National Strategy for Drugs for Rare Diseases. More than 650 patients, families, stakeholders, and patient organizations - like Jesse's Journey - provided their diverse perspectives on getting better access to the effective drugs they need. Throughout the [...]

NS Pharma: VILTEPSO® (viltolarsen) Injection Long-Term Efficacy and Safety Data

July 6, 2021

N.S. Pharma, Inc. has announced new long-term efficacy and safety data from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection. VILTEPSO is an exon-skipping therapy for individuals with Duchenne muscular dystrophy with deletion mutations amenable to exon 53 skipping. The efficacy and safety results were based on interim analyses at week [...]

Italfarmaco: Topline Data from Phase 2 Trial with Givinostat

July 2, 2021

Italfarmaco has announced results for their Givinostat trial in Becker muscle dystrophy (BMD). Although the change in total fibrosis in muscle biopsy did not show a significant difference in 51 adult males with BMD, it did show a significant difference from placebo on muscle MRI confirming the ability of Givinostat to counteract muscle deterioration. Italfarmaco [...]

Jesse’s Journey and PPPMD Award Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

June 16, 2021

Jesse's Journey and Parent Project Muscular Dystrophy Award $172,000 (CAD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility. Award Will Sponsor a Two-Year Fellowship Under Dr. Leanne Ward, the University of Ottawa with Focus on Endocrine and Bone Complications of Duchenne. Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end [...]

Research Grant Recipient: Satellos Bioscience

September 8, 2021

Jesse's Journey is proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne. Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The company's drug [...]

Longtime Volunteer Walks Across Canada

June 30, 2021

This Canada Day, long-time Jesse's Journey volunteer Harry Norris will complete his goal of walking across Canada - without leaving his hometown of Mitchell, Ontario. Beginning in March 2020, the 76-year-old retired school principal started a journey that saw him walk more than 8,200 kilometres - a distance that would take him coast to coast. [...]

Santhera and ReveraGen: Positive Topline Results with Vamorolone in VISION-DMD Study

June 1, 2021

Santhera and ReveraGen have announced positive topline results for vamorolone, a steroid alternative for individuals living with Duchenne muscular dystrophy (DMD). Their pivotal VISION-DMD study in boys 4 to <7 years old demonstrated benefits across multiply timed tests compared to placebo (boys not on treatment) and similar benefits to individuals taking prednisone. Vamorolone also showed [...]

Solid Biosciences: IGNITE DMD Phase I/II Clinical Trial Update

May 20, 2021

Jesse’s Journey is pleased to share the letter for the Duchenne community from Solid Biosciences, providing a business update and including a dosing update in the IGNITE DMD Phase I/II clinical trial and promising long-term biopsy data from prior patients dosed with SGT-001 in the high dose cohort at 2E14 vg/kg. They also announced the [...]

Sarepta Therapeutics: SRP-9001 (ENDEAVOR) Gene Therapy Study Update

May 20, 2021

Jesse’s Journey is pleased to share an update from Sarepta Therapeutics on their Gene Therapy for DMD SRP-9001. The results from the first 11 patients enrolled showed an increase in micro-dystrophin expression and a consistent safety profile. “We are delighted by these seminal results from the ENDEAVOR Study, our first trial results with SRP-9001 made [...]

World Duchenne Awareness Day: September 7, 2021

May 13, 2021

September 7 is World Duchenne Awareness Day. On this day, Jesse's Journey joins forces with organizations from around the world to raise awareness for Duchenne and Becker Muscular Dystrophy (DMD/BMD). Every year, the World Duchenne Organization sets a special theme to the day that that deserves more attention. This year it will be ‘Adult Life [...]

Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.

Jesse's Journey Foundation